Loading
A phase 2/3 trial of Oral paclitaxel in advanced solid tumours, run by Daehwa Pharmaceutical Co., Ltd., active and no longer recruiting.
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy is a phase 2/3 interventional study registered as NCT03315364 by Daehwa Pharmaceutical Co., Ltd., with 549 participants enrolled, started 2017-12-18 and due to reach its primary completion in 2024-02-19. Interventions recorded: Oral paclitaxel and Paclitaxel injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/